Zhou Jingwen, Wu Jiahui, Zhang Jintao, Xu Tan, Zhang Huan, Zhang Yonghong, Zhang Shaoyan
Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.
Department of Neurology, The 88th Hospital of Jinan Military Command, Tai'an, China.
J Stroke Cerebrovasc Dis. 2015 Jun;24(6):1250-5. doi: 10.1016/j.jstrokecerebrovasdis.2015.01.028. Epub 2015 Apr 20.
To investigate the association of short-term clinical outcomes with coexistence of hyperglycemia and elevated biomarkers of inflammation among acute ischemic stroke (AIS) patients.
We performed a retrospective study of 2675 patients diagnosed with AIS from January 2006 to December 2008. The study outcomes were defined as neurologic deficiency (National Institutes of Health Stroke Scale score ≥5) at discharge or death during hospitalization.
Compared with normoglycemia and without any elevated biomarkers, patients with hyperglycemia, elevated white blood cell (WBC) count, elevated neutrophils ratio (NEUR), and elevated erythrocyte sedimentation rate (ESR) had higher rates of study outcomes (all P < .05). Furthermore, patients with coexistence of hyperglycemia with any of elevated WBC count, NEUR, or ESR were more likely to have study outcomes (all P < .05). Compared with subjects with normoglycaemia and without any elevated biomarker, multivariate adjusted odds ratios (95% confidence interval) of study outcomes associated with hyperglycemia, elevated WBC count, elevated NEUR, elevated ESR, coexistences of hyperglycemia with elevated WBC count, elevated NEUR, and elevated ESR were 1.492 (1.139-1.955), 1.404 (1.048-1.881), 1.897 (1.411-2.551), 2.184 (1.339-3.564), 1.963 (1.337-2.883), 2.544(1.715- 3.775), and 2.687 (1.347-5.363), respectively.
This study indicated that hyperglycemia and elevated biomarkers of inflammation were associated with short-term clinical outcomes, and individuals with coexistence of hyperglycemia and elevated biomarkers of inflammation had higher risk of poor clinical outcomes among AIS patients.
探讨急性缺血性卒中（AIS）患者高血糖与炎症生物标志物升高并存与短期临床结局之间的关联。
我们对2006年1月至2008年12月诊断为AIS的2675例患者进行了一项回顾性研究。研究结局定义为出院时神经功能缺损（美国国立卫生研究院卒中量表评分≥5）或住院期间死亡。
与血糖正常且无任何炎症生物标志物升高的患者相比，高血糖、白细胞（WBC）计数升高、中性粒细胞比例（NEUR）升高和红细胞沉降率（ESR）升高的患者研究结局发生率更高（均P<0.05）。此外，高血糖与WBC计数、NEUR或ESR升高其中之一并存的患者更易出现研究结局（均P<0.05）。与血糖正常且无任何炎症生物标志物升高的受试者相比，高血糖、WBC计数升高、NEUR升高、ESR升高、高血糖与WBC计数升高并存、高血糖与NEUR升高并存以及高血糖与ESR升高并存相关的研究结局的多因素调整优势比（95%置信区间）分别为1.
